Oncotarget

Research Papers:

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer

Tommaso De Marchi _, Anne M. Timmermans, Marcel Smid, Maxime P. Look, Christoph Stingl, Mark Opdam, Sabine C. Linn, Fred C. G. J. Sweep, Paul N. Span, Mike Kliffen, Carolien H. M. van Deurzen, Theo M. Luider, John A. Foekens, John W. Martens and Arzu Umar

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:3098-3110. https://doi.org/10.18632/oncotarget.6521

Metrics: PDF 1081 views  |   HTML 1247 views  |   ?  


Abstract

Tommaso De Marchi1, Anne M. Timmermans1, Marcel Smid1, Maxime P. Look1, Christoph Stingl2, Mark Opdam3, Sabine C. Linn3, Fred C. G. J. Sweep4, Paul N. Span5, Mike Kliffen6, Carolien H. M. van Deurzen7, Theo M. Luider2, John A. Foekens1, John W. Martens1,8, Arzu Umar1

1Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands

2Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands

3Division of Medical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

4Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

5Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands

6Department of Pathology, Maasstad Hospital, Rotterdam, The Netherlands

7Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands

8Cancer Genomics Center Netherlands, Amsterdam, The Netherlands

Correspondence to:

Tommaso De Marchi, e-mail: t.demarchi@erasmusmc.nl

Keywords: tamoxifen resistance, annexin-A1, caldesmon, clinical proteomics, metastatic breast cancer

Received: July 30, 2015     Accepted: November 16, 2015     Published: December 09, 2015

ABSTRACT

Tamoxifen therapy resistance constitutes a major cause of death in patients with recurrent estrogen receptor (ER) positive breast cancer. Through high resolution mass spectrometry (MS), we previously generated a 4-protein predictive signature for tamoxifen therapy outcome in recurrent breast cancer. ANXA1 and CALD1, which were not included in the classifier, were however the most differentially expressed proteins. We first evaluated the clinical relevance of these markers in our MS cohort, followed by immunohistochemical (IHC) staining on an independent set of tumors incorporated in a tissue microarray (TMA) and regression analysis in relation to time to progression (TTP), clinical benefit and objective response. In order to assess which mechanisms ANXA1 and CALD1 might been involved in, we performed Ingenuity pathway analysis (IPA) on ANXA1 and CALD1 correlated proteins in our MS cohort. ANXA1 (Hazard ratio [HR] = 1.83; 95% confidence interval [CI]: 1.22–2.75; P = 0.003) and CALD1 (HR = 1.57; 95% CI: 1.04–2.36; P = 0.039) based patient stratification showed significant association to TTP, while IHC staining on TMA showed that both ANXA1 (HR = 1.82; 95% CI: 1.12–3.00; P = 0.016) and CALD1 (HR = 2.29; 95% CI: 1.40–3.75; P = 0.001) expression was associated with shorter TTP independently of traditional predictive factors. Pearson correlation analysis showed that the majority of proteins correlated to ANXA1 also correlated with CALD1. IPA indicated that ANXA1 and CALD1 were associated with ER-downregulation and NFκB signaling. We hereby report that ANXA1 and CALD1 proteins are independent markers for tamoxifen therapy outcome and are associated to fast tumor progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6521